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In two in vitro studies, we examined the immunological (pathways of the) eﬀects of Citrus/Cydonia comp. from, respectively, a
healthy and an allergic donor; peripheral blood mononuclear cells (PBMCs) were isolated out of peripheral blood and analyzed
in vitro after polyclonal stimulation of T-cells. The diﬀerentiation capacity and the influence with regard to Th1 (IFN-γ) and Th2
(IL-5) cells were examined. Citrus/Cydonia comp. has a selective eﬀect on the diﬀerentiation of T-cells by producing relatively
more IL-10 than IL-12. By that, it also seems to have an eﬀect on the induction of regulatory (IL-10 producing) T-cell subsets. It
is in vitro capable of neutralizing (to some extent) the changes, characteristic to allergic rhinitis, with regard to the maturation,
diﬀerentiation, and activity of the immune system. Thus, Citrus/Cydonia comp. can potentially restore the disturbed immune
state of rhinitis patients, which essentially could be suﬃcient to make allergic symptoms disappear permanently.
Copyright © 2008 E. W. Baars and H. F. J. Savelkoul. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
1. INTRODUCTION
Allergic rhinitis is a condition characterized by sneezing,
watery nasal discharge, and nasal obstruction and itching.
It is an increasingly prevalent condition, particularly in the
Western world where it aﬀects around 20% of the adult
population. Allergic rhinitis is divided into seasonal allergic
rhinitis (hay fever) which is triggered by pollens and moulds,
and perennial allergic rhinitis in which house dust mites and
pet dander are the predominant triggers. The spectrum of
severity is wide and includes a significant number of suﬀerers
with severe symptoms that are resistant to treatment with
usual pharmacotherapy (antihistamines and topical nasal
corticosteroids) [1]. The mean prevalence of allergic rhinitis
in several Western countries is 12% [2].
Seasonal allergic rhinitis or hay fever is a type I
immediate hypersensitivity reaction mediated by specific IgE
antibody to a seasonal allergen, leading to mucosal inflam-
mation characterized by sneezing, itching, rhinorrhoea, and
nasal blockage. Pollens (6–40 μm in diameter) from wind-
pollinated grasses, trees, weeds, and spores from fungi are
the most common aeroallergens. Grass pollen is the most
common cause of seasonal allergic rhinitis. The highest levels
of pollen in the atmosphereare found in May to July and
pollen concentrations of 50 grains/mm3 are associated with
symptoms in all susceptible people. The treatment of choice
of seasonal allergic rhinitis is the symptomatic treatment
with local or oral antihistamines and/or local corticosteroids.
Immunotherapy, including sublingual immunomodulation
therapy, is indicated in a limited subpopulation of patients
[3].
Citrus/Cydonia comp. is an anthroposophic medicine,
which contains extracts of lemon (Citrus lemon) and quince
(Cydonia oblongata) [4]. For over eighty years now, the
medicine “Citrus/Cydonia comp.” is being prescribed as a
subcutaneous injection or as a nasal spray for patients who
suﬀer from seasonal allergic rhinitis. A survey on clinical
experiences, carried out among a group of 39 active Dutch
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general practitioners [4], indicates that the subcutaneous
treatment with Citrus/Cydonia comp. ampoules is pro-
foundly eﬀective. Firstly, a permanent eﬀect from the treat-
ment with Citrus/Cydonia comp. tends to be experienced,
which indicates that the patients in question are claiming
to lastingly suﬀer less from hay fever or even that they
are free from complaints. Secondly, the eﬀect is occurring
within a period of two weeks, up to three months, after
the actual treatment. Thirdly, the eﬀect is optimal after a
treatment of several years. Moreover, the survey pointed
out that preventive administration before the start of the
pollen season with Citrus/Cydonia comp. may be even more
eﬃcacious to the patients in question. Recently, positive
eﬀects by Citrus/Cydonia comp. were obtained among a
group of 13 patients with the following characteristics: (a)
allergic to grass pollen, (b) suﬀering from hay fever, on
average, for nine years, and (c) the necessity for the use of
antihistamines with regard to the nature of the complaints
[5]. In addition, a prospective, observational study on the
eﬀect of Citrus/Cydonia comp. nasal spray on hay fever
symptoms reported positive results without side eﬀects in
140 patients [6]. We now performed in vitro studies to
study the possible immunological (pathways of the) eﬀects
of Citrus/Cydonia comp.
2. MATERIALS AND METHODS
2.1. Blood donors
From a healthy and an allergic individual, 8mL of blood
was collected in sodium heparinate-coated vacutainers (BD
Biosciences, San Diego, Calif, USA). The allergic individ-
ual was sensitized for birch pollen (RAST 6+) and grass
pollen (RAST 4+), and he was also food allergic with a
positive skin prick test on apple and cherry. The blood was
subsequently diluted 1:1 with IMDM containing GlutaMAX
(IMDM; Gibco-BRL, Paisley, Scotland) before the density
gradient centrifugation on Ficoll-Paque PLUS (Amersham
Biosciences, Uppsala, Sweden). The PBMC layer was washed
twice with IMDM and the cell viability and cell concentra-
tion were determined by Trypan blue exclusion. An informed
consent was obtained before the sample collection and the
performed experiments were approved by the local ethical
committee.
2.2. Culture conditions
PBMCs were cultured in Yssel’s medium at 37◦C in a
humidified atmosphere with 5% CO2 at a density of 1·106
viable cells/mL. Yssel’s medium consisted of IMDM supple-
mented with 1% Penicillin-Streptomycin (Gibco BRL), extra
additions according to Yssel et al. [1984], and 1% human
AB serum (Gibco BRL). Cells were plated out in 48 well
plates at a concentration of 1·106 cells/mL and cultured at
37◦C. After five hours of adaptation to the culture conditions,
the various stimuli or a matching volume of medium
were added. Cultures were stimulated with 150 ng/mL anti-
CD3 plus 100 ng/mL anti-CD28monoclonal antibodies (BD
Pharmingen, San Diego, Calif, USA) or cultured in medium
only [7].
2.3. Citrus/Cydonia comp. stimulation
Both conditions (negative and positive controls) took place
in the presence of Citrus/Cydonia comp. 100 μL/1mL
culture in two dilutions (undiluted and 1:3 dilution in
culture medium). The extract (Gencydo) was obtained from
(Weleda, Zoetermeer, The Netherlands).
2.4. Cell viability
Half a million PBMCs were washed and subsequently
incubated with 2 μL Annexin V-APC (BD Biosciences) in
200 μL Annexin V buﬀer according to the manufacturer’s
protocol. After an incubation period of 15minutes on ice, the
cells were spun down (400 g for 10minutes) and resuspended
in 200 μL Annexin V buﬀer and 2 μL PI (1mg/mL; Sigma,
St. Louis, Mo, USA). The cells were then analyzed on a flow
cytometer (FACS array, BD Biosciences).
2.5. Immunological phenotype
The immunological phenotype of PBMC subsets was deter-
mined by staining the surface antigens with the following two
monoclonal antibody (α) mixtures: (1) α-hCD3 (PE-Cy7),
α-hCD4 (PE), α-hCD8 (APC), and α-hCD25 (APC-Cy7);
(2) α-hCD3 (PE-Cy7), α-hCD14 (APC), α-hCD16 (PE), α-
hCD19 (APC-Cy7), and α-hCD56 (PE). All antibodies were
purchased at BD Biosciences .
Per well, 5·105 cells were spun down in a 96 wells U-
bottom plate. The cells were incubated with staining buﬀer
(1%FCS and 0.1M NaN3 in PBS) containing the surface
markers or the matching isotype controls for 30 minutes
on ice in the dark. The cells were washed once with PBS
and resuspended in PBS for flow cytometry. The four-color
flow cytometric acquisition was performed on an FACS array,
using the BD FACS-array software. An electronic gate was
set to exclude debris and at least 10 000 events/samples were
acquired. The percentages of positive cells were corrected for
the isotype control.
2.6. Proliferation capacity
The proliferation capacity of the PBMC was studied by
intracellular expression of the nuclear Ki-67 antigen (Ki-
67; BD Pharmingen). The Ki-67 antigen is absent in the
nuclei of resting cells, but present in all other phases of
the cell division cycle as well as in the mitosis phase [8].
In each well, 5·105 PBMCs were incubated with 100 μL
Cytofix/Cytoperm (BD Pharmingen) for 15–20 minutes on
ice to fix and permeabilize the cells. Cells were washed twice
with perm/wash buﬀer (BD Pharmingen) and incubated
with anti-Ki-67 PE antibody, or the matched isotype control,
diluted in perm/wash buﬀer for 30 minutes on ice in the
dark. Hereafter, the cells were washed with perm/wash buﬀer,
resuspended in PBS, and measured on the flow cytometer.
E. W. Baars and H. F. J. Savelkoul 3
Table 1: Mean scores after one day (healthy donor).
Medium Medium + Citrus/Cydonia comp. 1 Medium + Citrus/Cydonia comp. 1:3
Proliferation (%) 3 (1)∗ 13 (3) 1 (1)
Cell death (%) 88 (12) 82 (11) 87 (5)
Cytokines (pg/mL)
TNF-α 13 (4) 3315 (129) 13 (1)
IL-1β 25 (6) 3535 (147) 15 (2)
IL-10 22 (9) 918 (52) 12 (1)
IL-12 12 (3) 46 (12) 12 (2)
IFN-γ 15 (2) 55 (8) 25 (3)
IL-4 10 (2) 12 (1) 10 (1)
IL-5 12 (2) 28 (3) 10 (1)
Percentages of proliferating cells and cells in apoptosis of PBMC cultures of a healthy donor stimulated for one day with medium or Citrus/Cydonia undiluted
and 1:3 diluted. In the supernatants of these cultures, cytokines were measured by flow cytometric analysis in the Bead Assay Flex Sets system. Cytokine levels
in pg/mL. ∗All results are described with standard deviations (SDs).
Values are expressed as cells positive for the Ki-67 mAb
corrected for the isotype control.
2.7. Cytokines
PBMC culture supernatants were analyzed for their IL-1β,
IL-12, IFN-γ, TNF-α, IL-4, IL-5, IL-10, and IL-13 contents.
The cytokine production was measured with Cytometric
Bead Assay Flex Sets (BD Pharmingen). All buﬀers used
in this protocol were obtained from the BD CBA Soluble
Protein Master Buﬀer Kit (BD Pharmingen). Supernatants
were collected, stored at −20◦C, and tested within 2 weeks.
The procedure was performed according to the manufac-
turer’s protocol. The samples were measured on the FACS
array, using the FCAP software. The sensitivity limits for
quantitative determinations, according to the manufacturer,
were 1.1 pg/mL for IL-1β, 0.3 pg/mL for IL-4 and IFN-γ,
0.5 pg/mL for IL-5, 2.3 pg/mL for IL-10, 2.2 pg/mL for IL-12,
0.6 pg/mL for IL-13, and 0.7 pg/mL for TNF-α.
3. RESULTS
3.1. Effect of Citrus/Cydonia comp.
on healthy donor PBMC
PBMCS were isolated and analyzed for their subset com-
position. The percentages of the subsets PBMC were 63%
CD3+ T-cells (with 50.4% CD4+ Th-cells and 12.6% CD8+
Tc-cells), 8% CD19+ B cells, 5% CD14+ monocytes, and
12% CD16/CD56+ NK cells. After one day (Table 1) and
four days (Table 2) of culture, the results showed that
Citrus/Cydonia comp. not only induced T-cell proliferation
directly, but also activated monocytes resulting in a selective
cytokine production (TNF-α, IL-1β, IL-10, and IL-12).
However, Citrus/Cydonia comp. induced more IL-10 than
IL-12 production most likely derived from monocytes,
thereby stimulating the outgrowth of immunoregulatory
(IL-10) monocytes more than the immunoreactive (IL-
12) subsets of monocytes. These monocyte-related eﬀects
of Citrus/Cydonia comp. were detectable within one day
and were found in cultures with a normal therapeutic
dose. Subsequently, T-cell activation and proliferation were
suprastimulated by Citrus/Cydonia comp. over the poly-
clonal stimulation alone. Citrus/Cydonia comp. had no eﬀect
on cell survival and did appear to be toxic for PBMC cell
subpopulations.
3.2. Effect of Citrus/Cydonia comp.
on an allergic donor PBMC
After four days (Table 3), the results demonstrated that
Citrus/Cydonia comp. was able to restore the reduced IL-10
production in PBMC cultures of the allergic individuals. The
stronger immunoregulatory balance (IL-10) and a curbed
augmented Th2 response (a decrease of IL-4 and IL-5
production) was accompanied by an increased production of
IL-12 and a reduced production of IFN-γ. Even after 4 days,
monocyte stimulation by Citrus/Cydonia comp. was detected
by the production of TNF-α and IL-10.
4. DISCUSSION
Here, we show that Citrus/Cydonia comp. has a selective
eﬀect on the diﬀerentiation of T-cells with regard to the
production of cytokines; the production of IL-10 is relatively
larger than that of IL-12. By that, Citrus/Cydonia comp. also
seems to have an eﬀect on the induction of regulatory (IL-
10 producing) T-cell subsets. Hence, as a consequence, Cit-
rus/Cydonia comp. might be producing an allergy reducing
eﬀect, at which it does not concern Th1 induction and the
reduction of the allergen-specific Th2 response, bearing the
risk of induction of a chronic inflammation and very likely
even an increased risk for autoimmunity.
Recent developments mainly concern the field of
allergen-specific immunotherapeutic protocols. This
immunotherapy is widely believed to occur through
restoration of the disturbed Th1-Th2 balance [9–12], either
linked to the induction of allergen-specific (blocking) IgG4
antibodies, or to the induction of regulatory T-cell subsets.
The exact role which the regulatory T-cell subsets play with
regard to these mechanisms is not yet indistinct. With regard
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Table 2: Mean scores after four days (healthy donor).
Medium Anti-CD3/28
Medium +
Citrus/Cydonia
comp. 1
Medium +
Citrus/Cydonia
comp. 1:3
Stimulation +
Citrus/Cydonia
comp. 1
Stimulation +
Citrus/Cydonia
comp. 1:3
Proliferation (%) 3 (1)∗ 42 (8) 3 (1) 1 (1) 48 (11) 40 (2)
Cell death (%) 88 (12) 61 (11) 87 (8) 92 (11) 65 (12) 60 (6)
Cytokines (pg/mL)
TNF-α 13 (2) 8483 (987) 15 (2) 13 (2) 9647 (733) 8117 (566)
IL-1β 15 (3) 4134 35 (11) 15 (1) 4858 (247) 4037 (138)
IL-10 12 (2) 9553 18 (8) 12 (2) 12276 (566) 5662 (931)
IL-12 12 (1) 84 26 (9) 12 (2) 238 (87) 185 (77)
IFN-γ 15 (2) 34355 15 (1) 15 (2) 48800 (12778) 37750 (12501)
IL-4 12 (2) 134 12 (1) 12 (2) 55 (12) 106 (28)
IL-5 12 (2) 375 12 (2) 12 (1) 118 (45) 266 (56)
Percentages of proliferating cells and cells in apoptosis of PBMC cultures of a healthy donor stimulated for four days with medium alone, polyclonal
stimulation with anti-CD3 plus anti-CD28 antibodies, or polyclonal stimulation in the presence of Citrus/Cydonia preparation undiluted and 1:3 diluted.
In the supernatants of these cultures, cytokines were measured by flow cytometric analysis in the Bead Assay Flex Sets system. Cytokine levels in pg/mL. ∗All
results are described with standard deviations (SDs).
Table 3: Mean scores after four days (allergic donor).
Medium Stimulation with anti-CD3/28 Stimulation + Citrus/Cydonia comp.
Proliferation (%) 1 (1)∗ 48 (12) 57 (12)
Cell death (%) 78 (8) 59 (16) 55 (8)
Cytokines
TNF-α 10 (1) 5782 (154) 6893 (738)
IL-1β 10 (1) 2275 (339) 3772 (665)
IL-10 10 (1) 2331 (452) 7634 (1299)
IL-12 10 (1) 134 (26) 335 (89)
IFN-γ 10 (1) 9778 (452) 11668 (1638)
IL-4 10 (1) 456 (87) 138 (18)
IL-5 10 (1) 667 (154) 227 (85)
Percentages of proliferating cells and cells in apoptosis of PBMC cultures of an allergic donor stimulated for four days with medium alone, polyclonal
stimulation with anti-CD3 plus anti-CD28 antibodies, or in the presence of Citrus/Cydonia undiluted preparation. In the supernatants of these cultures,
cytokines were measured by flow cytometric analysis in the Bead Assay Flex Sets system. Cytokine levels in pg/mL. ∗All results are described with standard
deviations (SDs).
to the development of these immunotherapeutic protocols,
special allergen preparations, obtained from purified natural
or recombinant produced allergens, are necessary and need
to be developed.
Citrus/Cydonia comp. is likely to induce more regulatory
T-cells, whether CD4+CD25+Fosp3+ natural or antigen-
induced IL-10 and/or TGF-b producing Tr-cells, that are,
therefore, very immunosuppressive, and which are capable
of reducing allergen specifically activated Th2 cells. Our
results imply that Citrus/Cydonia comp. does not induce a
complete state of immunosuppression, resulting in a dimin-
ished resistance against infections and a reduced protection
against tumors. This is consistent with the long-term clinical
experiences and the results of the empirical studies on the use
of Citrus/Cydonia comp.
Based on these in vitro investigations, we hypothesized
that Citrus/Cydonia comp. is capable of neutralizing (to
some extent) the changes, characteristic to allergic rhinitis,
with regard to the construction, the maturation, the diﬀeren-
tiation, and the activity of the immune system. By that, it is
possible to explain the therapeutic positive eﬀects on allergic
rhinitis patients treated with Citrus/Cydonia comp. found in
previous studies and clinical practice.
The conclusions based on this study are of great impor-
tance, since the standard treatment of allergic rhinitis is
based on the long-term use of antihistamines, potentially
in combination with a local application of corticosteroids,
in case of persisting and/or serious symptoms. Those
treatments tend to reduce the symptoms, but they do not
possess any immunotherapeutic potency themselves. This
implies that it is compulsory for individual patients to keep
on using such medicines for many years. Based on our
pilot data, indicating that in vitro Citrus/Cydonia comp.
is capable of modulating the Th1-Th2 balance, we actually
expect Citrus/Cydonia comp. to have an immunotherapeutic
potency. This adds to the clinical therapeutic eﬀect from
E. W. Baars and H. F. J. Savelkoul 5
Citrus/Cydonia comp., both as an injection and as a topical
application. This implies that a long-term treatment with
Citrus/Cydonia comp. injections during several years, before
the start of the pollen season, can potentially restore the
disturbed immune state of rhinitis patients, which essentially
could be suﬃcient to make the allergic complaints disappear.
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